Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04100096 · ClinicalTrials.gov registry record · Phase 2
A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 332
- Enrollment target
NCT04100096 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 332 participants.
The verdict
NCT04100096, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 332 participants
- Enrollment target
Study Summary
There are currently no pharmacological treatments approved to treat borderline personality disorder (BPD). This trial will be conducted to evaluate the efficacy and safety of brexpiprazole for the treatment of participants diagnosed with BPD to provide a pharmacological treatment for BPD.
Interventions
- OTHER Placebo
- DRUG Brexpiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2021-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04100096
The ClinicalTrials.gov registry entry for NCT04100096 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04100096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04100096 about?
NCT04100096 is a clinical study titled "A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder". There are currently no pharmacological treatments approved to treat borderline personality disorder (BPD). This trial will be conducted to evaluate the efficacy and safety of brexpiprazole for the treatment of participants diagnosed with BPD to provide a pharmacological treatment for BPD.
What is the current status of trial NCT04100096?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 332 participants. The study started on 2019-10-17. Estimated completion is 2021-06-27.
What interventions are being tested in trial NCT04100096?
The interventions under investigation include: Placebo (OTHER), Brexpiprazole (DRUG).
Who is sponsoring clinical trial NCT04100096?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.